Alk-Abello A/S

11 patents currently held · Updated Nov 15, 2026

1 more in force is now held by another company

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 5 name spellings.

Ending by 2030

Dec 2027

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Apr 13, 2027
The maintenance fee for Stabilized composition comprising at least one adrenergic compound (US 9,155,694) comes due Apr 13, 2027. Unpaid by Oct 13, 2027, it lapses early.
3 fees due Aug 2 to 23, 2027 · next Aug 2

Which patents, and when each one lapses · Pro

Recent changes

1 term has ended since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 7,887,821	Process for producing an allergen extract In force Term ends Dec 20, 2027 · From the USPTO record	In force	Term ends Dec 20, 2027	From the USPTO record
US 8,703,903	Method for Quantification of Allergens In force Term ends Apr 24, 2028 · High confidence	In force	Term ends Apr 24, 2028	High confidence
US 9,248,097	Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season In force Term ends Apr 20, 2029 · From the USPTO record	In force	Term ends Apr 20, 2029	From the USPTO record
US 9,155,694	Stabilized composition comprising at least one adrenergic compound In force Ends no later than Jun 3, 2030 · From the USPTO record	In force	Ends no later than Jun 3, 2030	From the USPTO record
US 9,265,824	Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof In force Ends no later than Jun 3, 2031 · From the USPTO record	In force	Ends no later than Jun 3, 2031	From the USPTO record
US 10,842,866	Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof In force Ends no later than Jun 3, 2031 · From the USPTO record	In force	Ends no later than Jun 3, 2031	From the USPTO record
US 9,259,464	Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof In force Term ends Jul 8, 2031 · From the USPTO record	In force	Term ends Jul 8, 2031	From the USPTO record
US 10,874,736	Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof In force Term ends May 27, 2033 · From the USPTO record	In force	Term ends May 27, 2033	From the USPTO record
US 10,059,751	Peptide combinations and uses thereof in treating dust mite allergy In force Term ends Dec 23, 2034 · From the USPTO record	In force	Term ends Dec 23, 2034	From the USPTO record
US 11,020,527	Injector comprising a safety pin In force Term ends Jun 15, 2037 · From the USPTO record	In force	Term ends Jun 15, 2037	From the USPTO record

10 of 11 patents shown.

Pro members see all 11.

Pro members: see all 11 patents

Also on record, not counted in the 11: 1 patent in force now held by others · 26 lapsed for an unpaid fee · 9 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 pending · 36 no status recorded

List them